Stability of an autologous platelet clot in the pericardial sac: An experimental and clinical study

Rademakers, Leonard M.; Gründeman, Paul F.; Bolderman, Robert W.; Veen, Frederik H. van der

doi:10.1016/j.jtcvs.2008.10.012

Cited by 3 publications

(2 citation statements)

References 21 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rademakers et al studied PRP degradation (platelet concentration *1000 • 10 3 platelets/mL) in an animal study and found that the weight of autologous platelet clots was reduced to 16% of the initial weight after 30 min of incubation in the pericardial sac. 42 In vivo tissue-related factors regulate the secretion of GFs from platelets. In addition, recruited or cotransplanted cells may also secrete GFs.…”

Section: Discussionmentioning

confidence: 99%

AnIn VitroInvestigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering

Jalowiec

D’Este

Bara

et al. 2016

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) has been used for different applications in human and veterinary medicine. Many studies have shown promising therapeutic effects of PRP; however, there are still many controversies regarding its composition, properties, and clinical efficacy. The aim of this study was to evaluate the influence of different platelet concentrations on the rheological properties and growth factor (GF) release profile of PRP-gels. In addition, the viability of incorporated bone marrow-derived human mesenchymal stem cells (MSCs) was investigated. PRP (containing 1000 × 10(3), 2000 × 10(3), and 10,000 × 10(3) platelets/μL) was prepared from human platelet concentrates. Platelet activation and gelification were achieved by addition of human thrombin. Viscoelastic properties of PRP-gels were evaluated by rheological studies. The release of GFs and inflammatory proteins was measured using a membrane-based protein array and enzyme-linked immunosorbent assay. MSC viability and proliferation in PRP-gels were assessed over 7 days by cell viability staining. Cell proliferation was examined using DNA quantification. Regardless of the platelet content, all tested PRP-gels showed effective cross-linking. A positive correlation between protein release and the platelet concentration was observed at all time points. Among the detected proteins, the chemokine CCL5 was the most abundant. The greatest release appeared within the first 4 h after gelification. MSCs could be successfully cultured in PRP-gels over 7 days, with the highest cell viability and DNA content found in PRP-gels with 1000 × 10(3) platelets/μL. The results of this study suggest that PRP-gels represent a suitable carrier for both cell and GF delivery for tissue engineering. Notably, a platelet concentration of 1000 × 10(3) platelets/μL appeared to provide the most favorable environment for MSCs. Thus, the platelet concentration is an important consideration for the clinical application of PRP-gels.

show abstract

Section: Discussionmentioning

confidence: 99%

AnIn VitroInvestigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering

Jalowiec

D’Este

Bara

et al. 2016

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

show abstract

“…In late 2008, Bayer HealthCare announced that marketing of the product was temporarily suspended pending review of additional clinical studies (Stamou et al 2009). In spite of the adverse events associated with the drug in CABG patients, clinical studies continue to explore the application of aprotinin in other indications, both prophylactic and therapeutic, where the control of pathophysiological inflammatory cascades is desirable (Maffulli et al 2008;Orchard et al 2008;Rademakers et al 2009). Further, the Nordic Group obtained the rights to Trasylol ® following the opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency in February 2012, recommending that the marketing authorization for aprotinin to be reinstated in the European Union.…”

mentioning

confidence: 99%

Production of Pharmaceutical Grade Recombinant Native Aprotinin and Non-oxidized Aprotinin Variants Under Greenhouse and Field Conditions

Pogue

Vojdani

Palmer

et al. 2014

Commercial Plant-Produced Recombinant Protein Products

View full text Add to dashboard Cite

Production of pharmaceutical‐grade recombinant aprotinin and a monoclonal antibody product using plant‐based transient expression systems

Pogue¹,

Vojdani

Palmer

et al. 2010

Plant Biotechnology Journal

182

139

View full text Add to dashboard Cite

SummaryPlants have been proposed as an attractive alternative for pharmaceutical protein production to current mammalian or microbial cell-based systems. Eukaryotic protein processing coupled with reduced production costs and low risk for mammalian pathogen contamination and other impurities have led many to predict that agricultural systems may offer the next wave for pharmaceutical product production. However, for this to become a reality, the quality of products produced at a relevant scale must equal or exceed the predetermined release criteria of identity, purity, potency and safety as required by pharmaceutical regulatory agencies. In this article, the ability of transient plant virus expression systems to produce a wide range of products at high purity and activity is reviewed. The production of different recombinant proteins is described along with comparisons with established standards, including high purity, specific activity and promising preclinical outcomes. Adaptation of transient plant virus systems to large-scale manufacturing formats required development of virus particle and Agrobacterium inoculation methods. One transient plant system case study illustrates the properties of greenhouse and field-produced recombinant aprotinin compared with an US Food and Drug Administration-approved pharmaceutical product and found them to be highly comparable in all properties evaluated. A second transient plant system case study demonstrates a fully functional monoclonal antibody conforming to release specifications. In conclusion, the production capacity of large quantities of recombinant protein offered by transient plant expression systems, coupled with robust downstream purification approaches, offers a promising solution to recombinant protein production that compares favourably to cell-based systems in scale, cost and quality.

show abstract

Stability of an autologous platelet clot in the pericardial sac: An experimental and clinical study

Abstract: Autologous platelet gel is unstable both in vitro and in vivo, whereas platelet-rich fibrin remains intact in vitro and, compared with autologous platelet gel, is less subject to degradation in pigs and in patients.

Cited by 3 publications

References 21 publications

AnIn VitroInvestigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering

AnIn VitroInvestigation of Platelet-Rich Plasma-Gel as a Cell and Growth Factor Delivery Vehicle for Tissue Engineering

Production of Pharmaceutical Grade Recombinant Native Aprotinin and Non-oxidized Aprotinin Variants Under Greenhouse and Field Conditions

Production of pharmaceutical‐grade recombinant aprotinin and a monoclonal antibody product using plant‐based transient expression systems

Contact Info

Product

Resources

About